Introduction
============

The hypothalamic decapeptide GnRH is a central regulator of reproductive function in vertebrates ([@bib23]). Two GnRH isoforms are present in the chicken; cGnRH-I and GnRH-II ([@bib35]). There is no genomic DNA evidence for a third GnRH ligand in the chicken to date. Both cGnRH-I and GnRH-II stimulate LH release from chicken pituitary *in vitro* ([@bib14], [@bib24]) and *in vivo* ([@bib5], [@bib14], [@bib36], [@bib32]). LH secretion in response to GnRH-II is markedly greater than that to cGnRH-I in mature laying hens. However, this is not the case in juvenile chickens of either sex, nor the cockerel ([@bib37]).

There is conflicting evidence for an effect of cGnRH-I or GnRH-II on FSH *in vitro* ([@bib14], [@bib24]), and *in vivo* ([@bib19], [@bib4], [@bib8], [@bib32]). Probably, cGnRH-I does not directly stimulate FSH release, but may stimulate FSH biosynthesis, while a role of GnRH-II in FSH production has not been established ([@bib8], [@bib35]).

Immunisation of laying hens against cGnRH-I, but not against GnRH-II, results in a complete regression of the reproductive system and a decrease in plasma LH ([@bib38]), suggesting that gonadotrophin secretion is controlled by cGnRH-I rather than GnRH-II. This is consistent with the presence of cGnRH-I in the median eminence ([@bib22], [@bib38]) and the correlation between hypothalamic cGnRH-I peptide content and reproductive status ([@bib38]). In contrast, abundant levels of GnRH-II ([@bib22], [@bib38], [@bib46]) are not observed in the median eminence and no change in hypothalamic GnRH-II peptide content is seen in cockerels around the onset of puberty ([@bib38]). However, hypothalamic GnRH-II levels do decrease when the preovulatory release of LH is maximal or declining in the hen. Thus, GnRH-II may be involved in neuroendocrine events preceding ovulation ([@bib48]). In other avian species GnRH-II affects reproductive behaviour in ring doves and female soliciting behaviour in song sparrows ([@bib18], [@bib21]).

The specific receptor types through which the GnRH ligands elicit biological responses in the chicken are not known. GnRH systems exhibit species-specific recruitment of receptor subtypes and ligands within different tissues. For example, the sea bass expresses five isoforms of GnRH receptor and all but one are expressed in the pituitary ([@bib26]). In goldfish, two subtypes of the GnRH receptor have been identified ([@bib16]) and they are both expressed in the pituitary. In the bullfrog, three subtypes of GnRH receptor are expressed but only one predominates in the pituitary ([@bib47]). Two subtypes of GnRH receptor occur in the African clawed frog (*Xenopus laevis*; [@bib45]) whereas the leopard gecko expresses three receptor subtypes in the pituitary, with one receptor subtype predominating in the anterior pituitary ([@bib15]). The pituitary-specific GnRH receptor subtypes expressed in the bullfrog ([@bib47]), African clawed frog ([@bib45]) and leopard gecko ([@bib15]) differ structurally, according to the nomenclature proposed by Miller *et al*. and phylogenetically ([@bib25], [@bib13], [@bib44]). The predominant pituitary GnRH receptor subtype expressed in the bullfrog is type III, the African clawed frog is type I and the leopard gecko is type III. This suggests plasticity in evolutionary recruitment of GnRH receptor subtypes for regulation of pituitary gonadotrophin production. There is also plasticity in the spatiotemporal expression patterns of GnRH receptor subtypes ([@bib16], [@bib45], [@bib47], [@bib26], [@bib15]).

The promiscuity of receptor subtype activation by different endogenous GnRH ligands ([@bib16], [@bib45], [@bib47], [@bib26], [@bib15]) suggests that a complex interplay between ligands and receptors may occur. The organisation of the avian GnRH system is distinct from those of teleosts, amphibians, reptiles or mammals (Ensemble database), having two receptor subtypes for two GnRH ligands ([@bib27]). Further characterisation of the avian GnRH system may therefore provide unique information to enable further comprehension of the interplay between GnRH ligands and their receptors in the control of reproduction.

The first chicken GnRH-R isoform to be cloned, cGnRH-R-I is widely expressed ([@bib42],[@bib43]) and GnRH-II has a higher binding affinity and is more potent in stimulating inositol phosphate accumulation than cGnRH-I at this receptor ([@bib43]). This suggested that the chicken pituitary might contain an alternative GnRH receptor more selective for cGnRH-I, since this appears to be the GnRH isoform most likely to be biologically important for regulation of LH production. A novel isoform of cGnRH-R was subsequently cloned by ourselves and others ([@bib17], [@bib39]; Genbank [AY895154](genbank:AY895154)). The white Leghorn isoform of the novel receptor was designated cGNRHR2 ([@bib39]), but it can be classified as a type III GnRH receptor. Using PCR, this receptor showed expression of two pituitary-specific transcripts (1260 bp full length and 1065 bp splice variant; [@bib39]), in addition to another 501 bp splice variant that is expressed in different brain regions ([@bib39]). Inositol phosphate accumulation in response to GnRH-II stimulation was more potent at cGNRHR2 ([@bib39]) than the response to cGnRH-I. Pituitary cGNRHR2 mRNA expression levels correlated with reproductive status, suggesting that cGNRHR2 plays a role in the regulation of gonadotroph function ([@bib39]).

The aims of this study were to undertake further characterisation of this second GnRH receptor isoform from a broiler chicken (commercial meat-type chicken) and compare it with the type I receptor. Using bioinformatics analysis, we confirm that cGNRHR2 is a chicken type III GnRH receptor homologue. Critically, we have established the preponderance of cGNRHR2 mRNA relative to cGnRH-R-I mRNA in the pituitary and expression was investigated during sexual development and the levels were quantified in a panel of tissues. We also performed ligand induced internalisation studies of both receptors and a detailed pharmacological analysis of the two receptors. This included analysis of ligand binding and inositol phosphate production in response to cGnRH-I and GnRH-II and an array of analogues and antagonists in order to identify a GnRH analogue that may be applied to examine receptor-specific effects on gonadotrophin production.

Materials and Methods
=====================

Animals
-------

Birds were killed in accordance with UK Home Office guidelines. Tissues were dissected, snap frozen in liquid nitrogen and stored at −70 °C.

Peptides/primers
----------------

GnRH analogues, cGnRH-I, GnRH-II and sGnRH-III (Sigma--Aldrich) and mammalian antagonists 27, 135-25 and 135-18 were diluted in 20% propylene glycol (Sigma--Aldrich). Sequences are presented in [Table 1](#tbl1){ref-type="table"}. \[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH peptide was synthesised with solid-phase methodology and purified by reverse-phase HPLC ([@bib10]). Oligonucleotides (Sigma--Aldrich) diluted to 100 pM/μl were used for PCR amplification and probe synthesis.

Cloning of cGNRHR2 cDNA
-----------------------

Trizol (Invitrogen) was used to isolate total RNA from pooled mature male and female anterior pituitary glands from broilers. cDNA synthesis was performed with 5 μg total RNA using a first strand synthesis kit (Amersham Pharmacia Biotech Ltd). Genbank [AY895154](genbank:AY895154) was used as a reference for design of cDNA primers. Primers 1210f (5′-TGAGTGGGCGGTGTTTGA-3′) and 3217r (5′-TAGAGGCATTGTGGAGCAGA-3′) encompassing the entire coding region of the receptor were used for PCR amplification of pituitary cDNA (35 cycles of 95 °C/30 s, 61·9 °C/30 s, 72 °C/90 s). The product was cloned into Bluescript II SK^(+)^ vector (Stratagene, The Netherlands) at the EcoRV site. The entire cDNA insert was sequenced. To make an expression construct, the fragment between the BamHI and HincII restriction sites of the Bluescript II SK^(+)^ construct was removed and subcloned into the pCDNA3.1/myc-His-A (Invitrogen) mammalian expression vector between the BamHI and EcoRV sites. The DNA sequence of the expression construct was verified by BamHI, BsmI and PstI restriction digest and sequencing.

An expression construct containing cGnRH-R-I cDNA cloned into pcDNA1/Amp (Invitrogen) eukaryotic expression vector was used ([@bib43]) in parallel studies.

Oligonucleotide probes
----------------------

5′ end labelling using \[γ-^32^P\]-dATP and T4 polynucleotide kinase was performed with 20 pmol sense (5′-TGGTGCCGATGTGGGAGCGCTGGGAGCAGTGAGTGGGCGGTGTT TGA-3′) and anti-sense (5′-TCAAACACCGCCCACTCACTGCTCCCAGCGCTCCCACAT CGGCACCA-3′) oligonucleotides using the mirVana Probe and Marker Kit (Ambion, USA). These oligonucleotides, designed in the 5′ region upstream of the translation start site in exon 1 are specific for cGNRHR2 and are not homologous to cGnRH-R-I.

DNA probes
----------

An actin alpha-1 skeletal muscle (ACTA1; Genbank [001031063](genbank:001031063)) DNA probe was synthesised from 0·25 μg purified insert DNA by random primer labelling with ^32^P-dCTP using a Rediprime Kit (GE Healthcare, UK) and purified using Sephadex G50 Nick columns (GE Healthcare).

Riboprobes
----------

A riboprobe was synthesised by *in vitro* transcription of 1 μg of the cGNRHR2 construct linearised with EcoRI using the T7 promoter and a kit (Promega) with ^\[32P\]^UTP (800 Ci/mmol, Amersham; specific activity of 30 TBq/mmol). Free nucleotides were removed using a Sephadex G50 column (GE Healthcare).

Northern blot analysis
----------------------

Ultraspec II (AMS Biotechnology Ltd, UK) was used to isolate total RNA from ten 14-week-old males of an advanced intercross of broiler and layer strain population. Poly(A)^+^ RNA was purified from anterior pituitary gland, testes and small intestine total RNA using Oligotex mRNA Spin-Columns (Qiagen). Three micrograms poly(A)^+^ RNA were loaded onto a formaldehyde gel and blotted using standard methodology.

Total RNA was also prepared from pituitary gland, brain cortex and skeletal muscle from sexually mature male and female white Leghorn layer type birds. Fifteen micrograms RNA were prepared for northern blotting according to the method of Pelle & Murphy (1993).

Tissue distribution of cGNRHR2 and quantification relative to cGnRH-R-I
-----------------------------------------------------------------------

Total RNA was prepared from 3 male and 3 female, 6-week-old (pre-pubertal) Ross broiler type birds raised on 21 h light:3 h darkness and 3 male and 3 female, 24-week-old (sexually mature) Ross broiler breeder birds raised on 14 h light:10 h darkness. cDNA synthesis was performed on 0·5 μg of total RNA, using a 1st Strand Synthesis Kit (Amersham Pharmacia Biotech Ltd). Primers that spanned exon boundaries, 713--735f (5′-GCTCGCTGTGCCGCAGCTGT-3′; exon 2--3) and 933--952r (5′-ACGTCCCTGGAGGAGAAGAG-3′; exon 3--4) were used to amplify cGNRHR2 from various tissue cDNA samples of the pre-pubertal males and females (40 cycles of 95 °C/30 s, 62 °C/30 s, 72 °C/45 s). Real Time PCR was used to quantify the mRNA expression of cGnRH-R-I and cGNRHR2 in the pituitary gland, median eminence, small intestine and gonad using the recommended amplification conditions using SYBR-Green-I-dye (Invitrogen). Primers that spanned the exon boundaries: 713--735f and 933--952r for cGNRHR2 cDNA and primers 701--722f and 1100--1082r for cGnRH-R-I cDNA were used with pre-pubertal and sexually mature male and female tissue samples. Standard curves for amplification of each GnRH receptor homologue cDNA were made with known quantities of either chicken GnRH receptor cDNA. The cGNRHR2 cDNA in Bluescript II SK^(+)^ vector and a cGnRH-R-I cDNA in Bluescript II SK^(+)^ vector (containing 488 bp inserted into the EcoRV/NotI site of the vector, which corresponds to bases 1--421 of [AJ304414](genbank:AJ304414) and 1--68 of [AJ506779](genbank:AJ506779)) were used. A linear regression analysis of known quantities of cDNA template versus cycle threshold values was plotted, allowing the calculation of the quantity of target nucleic acid from the test-sample cycle threshold values. PCR reaction with either template reached plateau phase following the same number of amplification cycles.

Iodination of \[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH
----------------------------------------------------

\[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH-I peptide was radioactively labelled with Iodine^125^ using Chloramine-T (Sigma--Aldrich) and purified using Sephadex G25 chromatography (Sigma--Aldrich).

Cell culture and gene transfection
----------------------------------

COS-7 cells were transiently transfected by electroporation with 10 μg expression construct. The cells were seeded in DMEM (Sigma--Aldrich) containing a final concentration of 10% FCS, 4 mM [l]{.smallcaps}-glutamine and 1×penicillin/streptomycin and incubated in a humidified atmosphere at 37 °C in 5% CO~2~.

Whole cell radioligand binding assay
------------------------------------

Radioligand binding assays were performed with ^125^I-\[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH-I on intact cells 48 h after transfection. Cells were washed twice with 4 °C PBS+Ca^2+^+Mg^2+^ (Sigma--Aldrich). The cells were then incubated for 4 h at 4 °C with ^125^I-\[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH (100 000 c.p.m./500 μl) and various concentrations of unlabelled GnRH analogues in 25 mM DMEM+HEPES+0·1% BSA in triplicate. Cells were then washed twice with PBS+Ca^2+^+Mg^2+^ and lysed with 0·1 M NaOH. Radioactivity was measured and non-specific binding was determined by displacement of label with 1 μM unlabelled GnRH analogue.

Inositol phosphate assay
------------------------

Total inositol phosphate accumulation in response to GnRH stimulation was analysed as previously described ([@bib2], [@bib30]) with modifications: 24 h after transfection, cells were labelled with 1 μCi/ml per well \[^3^H\]-myo-inositol, (Amersham Pharmacia Biotech) in 1 ml of inositol-free DMEM (Invitrogen Life Sciences) and incubated for a further 24 h. Cells were incubated at 37 °C with 0·5 ml 25 mM DMEM+HEPES (Sigma--Aldrich) containing 10 mM LiCl for two successive 5 and 30 min washes prior to stimulation with GnRH analogue in DMEM+HEPES+10 mM LiCl for 1 h. Antagonist activity was assayed in the presence of 1 nM GnRH-II. Stimulations were terminated by replacing medium with 10 mM formic acid and incubating at 4 °C for 1 h. Water-soluble metabolites were separated as previously described ([@bib3]) with a series of washes of the Dowex resin with H~2~O and 60 mM ammonium formate, 5 mM sodium tetraborate prior to inositol phosphate elution in 1 M ammonium formate, 0·1 M formic acid. Assays were performed in triplicate.

Receptor internalisation assays
-------------------------------

Receptor-transfected cells were incubated for 48 h prior to performing the internalisation assay as previously described ([@bib29]). Modifications to the protocol included addition of 0·5 ml acid solution (150 mM NaCl, 50 mM acetic acid, pH 2·8) to determine surface bound ligand and 0·5 ml 1 M NaOH for internalised radioligand. Non-specifically bound ligand was measured at time point zero and used to normalise data. Assays were performed four times with six replicate points per experiment.

Statistical analysis
--------------------

ANOVA was performed on Real time PCR data using GenStat version 9 (VSN International Ltd, UK). Other results were analysed using GraphPad Prism version 4.0 (GraphPad Software, CA, USA). Non-linear regression models were applied to the ligand binding and inositol phosphate assay data. Receptor internalisation rates were analysed as previously described ([@bib29]).

Results
=======

Cloning of the cGNRHR2 cDNA
---------------------------

We cloned a PCR cDNA product from broiler (meat-type birds) pituitary samples that was identical to the sequence from *Gallus gallus gallus* genomic DNA (ENSGALG00000020923; Ensembl 2004) and White Leghorn strains (Genbank [AY895154](genbank:AY895154)). An expression construct containing the entire coding sequence, 24 bp 5′ to the start codon and 100 bp 3′ to the stop codon was prepared.

Gene structure of cGNRHR2
-------------------------

Bioinformatic comparisons of the cDNA and genomic DNA sequences confirmed that the receptor consists of a 419 amino acid protein encoded by 4 exons ([@bib39]) on chicken chromosome 10 linked to the type I receptor. The amino acid sequence identity of the two cGnRH-Rs is 53% ([Fig. 1](#fig1){ref-type="fig"}A). The amino acid sequences of both cGnRH-R receptors were compared with human, bullfrog, leopard gecko and African clawed frog GnRH receptor subtypes. The highest homology to cGnRH-R-I was with bullfrog-II GnRH-R. The highest homology to cGNRHR2 occurred with bullfrog-I and leopard gecko-I GnRH-Rs. Phylogenetic analysis performed by ourselves ([Fig. 1](#fig1){ref-type="fig"}B) and others ([@bib13], [@bib44]) clearly classes this receptor as a type III GnRH receptor homologue. We therefore refer to it as cGnRH-R-III from here on.

The putative translation start codon is coded by exon 1 and the stop codon by exon 4. The amino terminal extracellular domain is coded by exon 1 and exon 2. Exon 2 also encodes transmembrane domain (TMD) 1, intracellular loop (ICL) 1, TMD2, extracellular loop (ECL) 1, TMD3, ICL2 and part of TMD4. Exon 3 encodes the rest of TMD4, ECL2, TMD5 and part of ICL3. Exon 4 encodes the rest of ICL3, TMD6, ECL3, TMD7 and the C-terminal cytoplasmic domain ([Fig. 1](#fig1){ref-type="fig"}A).

Comparisons of functionally important residues and micro-domains were performed. cGnRH-R-III like cGnRH-R-I has aspartic acid in both loci of the helix2/helix7 micro-domain, an arrangement unique to non-mammalian GnRH receptors ([@bib50], [@bib11]; [Fig. 1](#fig1){ref-type="fig"}A). Conservation of important coupling motifs, the arginine cage motif ([@bib1]) and alanine in ICL3 ([@bib28]) is maintained in cGnRH-R-III ([Fig. 1](#fig1){ref-type="fig"}A). The two cGnRH-Rs exhibit conservation of the aspartic acid ([@bib12]) and asparagine ([@bib7]) ligand-binding residues in TMD2 ([Fig. 1](#fig1){ref-type="fig"}A). The lysine in TMD3 of the cGnRH-R-III ([@bib51]) is substituted with an arginine residue. The glutamate residue in ECL3 ([@bib9]) is not conserved in cGnRH-R-III whereas it is in cGnRH-R-I ([@bib43]). ECL3 of each receptor type has a distinctive classification motif ([@bib25]), *cGnRH-R-I* has a PEY motif in ECL3 whereas in cGnRH-R-III this motif is PPS ([Fig. 1](#fig1){ref-type="fig"}A). The motifs known to be crucial for receptor internalisation were compared ([@bib29], [@bib30]), and are conserved between cGnRH-R-I and cGnRH-R-III, however, the tail of cGnRH-R-III is longer by an additional eight residues ([Fig. 1](#fig1){ref-type="fig"}A).

Northern blot analysis
----------------------

Hybridisation of cGnRH-R-III antisense oligonucleotide probe was detected in the anterior pituitary but not testes or small intestine RNA ([Fig. 2](#fig2){ref-type="fig"}A). The cGnRH-R-III mRNA transcript is approximately 1600 bases long. Sense oligonucleotides did not hybridise to the RNA samples (data not shown). ACTA1 skeletal muscle ^32^P-dCTP labelled DNA probe hybridised to all samples ([Fig. 2](#fig2){ref-type="fig"}B), demonstrating equal RNA loading. A riboprobe also detected cGnRH-R-III mRNA transcripts of approximately 1600 bases in male and female anterior pituitary but not brain cortex or skeletal muscle RNA ([Fig. 2](#fig2){ref-type="fig"}C). There was no evidence of cGnRH-R-III mRNA transcript size variants in any tissues.

Tissue distribution of cGnRH-R-III expression and quantification relative to cGnRH-R-I
--------------------------------------------------------------------------------------

PCR amplification of GnRH receptor cDNA was ensured by designing primers spanning exon boundaries. A single 238 bp cDNA amplification product derived from exon 3 was detected in the pituitary. Amplification of cGnRH-R-III cDNA was detected in all tissues tested (anterior pituitary, hind-brain, cerebrum, cerebellum, median eminence, anterior hypothalamus, posterior hypothalamus, olfactory bulb, optic lobe, adrenal gland, kidney, small intestine, spleen, testes, ovary and liver) from pre-pubertal males and females although the signal intensity in the anterior pituitary was distinctly the highest. Relative levels of cGnRH-R-I and cGnRH-R-III mRNA measured by real-time PCR in juvenile and mature male and female tissues demonstrated that expression of cGnRH-R-III was greater than cGnRH-R-I in the pituitary, median eminence, gonads and small intestine. In the anterior pituitary cGnRH-R-III expression was 1373-fold that of cGnRH-R-I ([Fig. 2](#fig2){ref-type="fig"}F). Even though the amplification efficiency of the two targets was similar, higher cGnRH-R-III expression was detected in the anterior pituitary compared with the median eminence, gonads and small intestine ([Fig. 2](#fig2){ref-type="fig"}D). Anterior pituitary expression of cGnRH-R-III was 92·5× greater than in the testes or ovary. Expression of cGnRH-R-I in the testes was 2-fold greater than in the anterior pituitary ([Fig. 2](#fig2){ref-type="fig"}E).

ANOVA demonstrated a significant relationship between age and sex on pituitary cGnRH-R-III expression ([Fig. 2](#fig2){ref-type="fig"}G). Anterior pituitary cGnRH-R-III expression was 8·4-fold lower in sexually mature males compared with juvenile males whereas the reciprocal relationship was observed in females, with 2·8-fold more anterior pituitary cGnRH-R-III expression in sexually mature females compared with juveniles ([Fig. 2](#fig2){ref-type="fig"}G).

Whole cell GnRH binding assays
------------------------------

Cells transfected with cGnRH-R-III and cGnRH-R-I expression constructs showed binding and displacement of ^125^I-\[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH with both cGnRH-I and GnRH-II in a concentration dependant fashion. The binding affinities for cGnRH-I and GnRH-II were similar at cGnRH-R-I and cGnRH-R-III ([Fig. 3](#fig3){ref-type="fig"}A). cGnRH-R-III exhibited a 35-fold higher affinity for GnRH-II than for cGnRH-I ([Table 2](#tbl2){ref-type="table"}). cGnRH-R-I exhibited a 21-fold higher affinity for GnRH-II than for cGnRH-I, similar to previous reports ([@bib43]).

cGnRH-R-III and cGnRH-R-I bound sGnRH-III and mammalian antagonists 27, 135-18 and 135-25 ([Table 2](#tbl2){ref-type="table"}). Because there was no genomic evidence for GnRH-III in the chicken, the binding affinity for sGnRH-III was tested as an alternative. cGnRH-R-III and cGnRH-R-I exhibited a 16-fold higher affinity for GnRH-II than for sGnRH-III, and both receptors exhibited a higher affinity for sGnRH-III than cGnRH-I ([Table 2](#tbl2){ref-type="table"}). Similar binding affinities were observed for all GnRH analogues and mammalian antagonists at either receptor except for mammalian antagonist 27.

cGnRH-I, GnRH-II, sGnRH-III, mammalian antagonist 135-18 and 135-25 showed respectively a 1·8, 1·1, 1·1, 3·5 and 0·6-fold higher binding affinity at cGnRH-R-I compared with cGnRH-R-III. Remarkably, cGnRH-R-I has a much higher affinity for mammalian antagonist 27 (*K*~d~: 0·38 nM) than cGnRH-R-III (*K*~d~: 21·4 nM).

Inositol phosphate assays
-------------------------

cGnRH-I and GnRH-II stimulated inositol phosphate production in cGnRH-R-I and cGnRH-R-III transfected cells ([Fig. 3](#fig3){ref-type="fig"}B). The ED~50~ for GnRH-II was much lower than for cGnRH-I, in accordance with their binding affinities. GnRH-II was more potent than cGnRH-I at either receptor. In cGnRH-R-III transfected cells, the accumulation of inositol phosphate was six times more effective with GnRH-II stimulation than with cGnRH-I ([Table 2](#tbl2){ref-type="table"}). GnRH-II was four times more potent than cGnRH-I for production of inositol phosphate via activation of cGnRH-R-I ([Table 2](#tbl2){ref-type="table"}). The ED~50~ for sGnRH-III was much higher than GnRH-II and cGnRH-I at both cGnRH-Rs ([Table 2](#tbl2){ref-type="table"}). In response to cGnRH-I, GnRH-II or sGnRH-III there was a 1·6, 1·1 and 2·0-fold higher potency at cGnRH-R-I compared with cGnRH-R-III.

Mammalian antagonist 27 displayed inverse agonist properties at either receptor, decreasing inositol phosphate production below basal levels for both receptors ([Fig. 4](#fig4){ref-type="fig"}A and C). Mammalian antagonist 135-25 stimulated inositol phosphate production with very low efficacy in transfected COS-7 cells: cGnRH-R-I (ED~50~: 5970 nM) and cGnRH-R-III (ED~50~: 4860 nM; [Table 2](#tbl2){ref-type="table"} and [Fig. 4](#fig4){ref-type="fig"}E and G). Mammalian antagonist 135-18 stimulated inositol phosphate in transfected COS-7 cells; cGnRH-R-III (ED~50~: 1510 nM) with weak efficacy, but no stimulation of inositol phosphate was detected in cGnRH-R-I transfected cells ([Fig. 4](#fig4){ref-type="fig"}I and K).

Inhibition of 1 nM GnRH-II-stimulated inositol phosphate production by mammalian antagonist 135-18 in cGnRH-R-I transfected COS-7 cells (IC~50~: 2330 nM) was more potent than for cGnRH-R-III (IC~50~: 3890 nM) transfected COS-7 cells ([Fig. 4](#fig4){ref-type="fig"}J and L). Mammalian antagonist 135-25, acted as a pure agonist in cGnRH-R-III transfected cells in the presence of 1 nM GnRH-II, increasing the potency of inositol phosphate stimulation from ED~50~: 4860 nM in the absence of GnRH-II to ED~50~: 20·1 nM in the presence of GnRH-II ([Fig. 4](#fig4){ref-type="fig"}H). Antagonistic properties for mammalian antagonist 135-25 were observed at cGnRH-R-I (IC~50~: 245 nM) transfected cells, but with little efficacy ([Fig. 4](#fig4){ref-type="fig"}F). Surprisingly, mammalian antagonist 27 exhibited large differences in antagonistic potency at cGnRH-R-I (IC~50~: 2·3 nM) compared with cGnRH-R-III (IC~50~: 351 nM; [Fig. 4](#fig4){ref-type="fig"}B and D).

Receptor internalisation assays
-------------------------------

The initial rate of internalisation of ^125^I-\[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH-I bound to cGnRH-R-III was slightly greater (*P*\<0·006) than cGnRH-R-I. cGnRH-R-I internalised at an initial rate of 15·8%/min whereas the initial rate of internalisation of cGnRH-R-III was determined as 26·0%/min. The per cent maximal internalisation of cGnRH-R-I was 78·2 vs 68·9% for GnRH-R-III ([Fig. 3](#fig3){ref-type="fig"}C).

Discussion
==========

Birds, like mammals, possess two GnRH receptor subtypes in contrast to fish, reptiles and amphibians in which three types of receptor are generally found ([@bib27], [@bib15]). The proximity of the two chicken receptor subtypes on chromosome 10 (∼2 Mb apart) and their high sequence similarity, suggests they may have been derived by gene duplication.

There has been an inclination to designate GnRH receptors that are selective for GnRH-II as type II GnRH receptors. However, all non-mammalian receptors, regardless of their structural similarity are selective for GnRH-II ([@bib31]). Other investigators have designated GnRH receptors by their tissue-specific expression. This classification is also problematic as the predominant GnRH receptor expressed in bullfrog pituitary is structurally a type III receptor ([@bib47]) while in African clawed frog, it is a type I receptor ([@bib45]). We therefore advocate that the receptors are grouped and designated according to their structural and phylogenetic relatedness. cGnRH-R-III was first designated as cGNRHR2 ([@bib39]), whereas designation as cGnRH-R-III is appropriate according to phylogenetic classification.

Delineation of 'cognate' ligand/receptor pairing requires the demonstration of receptor protein expression in the target cell and demonstration of ligand isoform delivery to that cell. In the chicken there is good evidence ([@bib22], [@bib38], [@bib46]) that cGnRH-I targets the gonadotroph and the higher expression levels of GnRH-R-III in the pituitary suggest that it is the cognate pituitary receptor. Expression of cGnRH-R-III was 1373-fold higher than cGnRH-R-I in the anterior pituitary gland. However, GnRH-R-III localisation to the gonadotroph remains to be demonstrated. Therefore, the development of analogues that differentially promote or inhibit activation of receptor subtypes may be valuable tools for deciphering the role of receptor types in terms of gonadotrophin regulation or other putative functions.

No sex differences or changes in expression were detected for cGnRH-R-I, however, a pronounced reciprocal sex difference in pituitary cGnRH-R-III expression was observed. Higher cGnRH-R-III mRNA levels occur in adult females compared with adult males. In contrast, in juvenile chickens, higher cGnRH-R-III mRNA levels occurred in males compared with females. cGnRH-R-III splice variant transcripts detected by PCR amplification ([@bib39]) were not detected by oligonucleotide probe or riboprobe using northern blotting, suggesting that their *in vivo* expression is relatively low and may be of little functional significance.

Differences in cGnRH-R-III receptor expression levels between juvenile and mature males and females were not reported previously ([@bib39]). This may be due to the age of animals used in different studies. The sexual dimorphism in cGnRH-R-III expression, where levels of mRNA are higher in juvenile males compared with juvenile females, is consistent with the LH response to photo-stimulation seen in juveniles, where there is a robust response in males but not in females ([@bib40]). However, in adult males and females, cGnRH-R-III expression levels are inversely related to sex differences in LH responsiveness to GnRH injection ([@bib37]). When chicken pituitary fragments from adult males and juveniles of both sexes are perifused, a large spike followed by a plateau in LH release in response to GnRH stimulation is observed ([@bib20]). Adult laying hens do not exhibit the rapid spike of release but do show the plateau phase and the release of LH in adult hens is much reduced compared with juvenile hens ([@bib20]). In general, our observations suggest that the level of GnRH-R-III mRNA may be inversely related to the release of LH by gonadotrophs in adult females. There are several possible explanations for this apparent paradox. However, cGnRH-R-III mRNA may be reflective of expression of membrane cGnRH-R-III receptor number, but that increased ovarian steroid and peptide hormones act negatively in the adult female to diminish the LH response to GnRH at the gonadotroph, through down-regulation of intercellular signalling pathways including the Ca^2+^ mobilisation mechanism ([@bib20]).

As noted above, the occurrence of two or three forms of GnRH peptide hormone in different vertebrate species initially suggested the existence of different cognate receptors able to differentially recognise the different ligands. Selectivity for GnRH-II is emerging as a general phenomenon for non-mammalian GnRH receptors due to the preconfigured β-II′ turn of GnRH-II ([@bib31]). The current study supports this concept in that both cGnRH-Rs maintain higher ligand selectivity for GnRH-II. This presents a conundrum in that cGnRH-I is the hypothalamic peptide regulating the gonadotroph ([@bib22], [@bib38]). GnRH-II was more potent at stimulating inositol phosphate production at the cGnRH-R-III than cGnRH-I. Similarly, GnRH-II stimulates inositol phosphate production four times more potently at cGnRH-R-I than cGnRH-I, consistent with previous data ([@bib43], [@bib39]). Since inositol phosphate and diacyl-glycerol are generated by the recruitment of the Gq protein and activation of PLC-β ([@bib41], [@bib33]), cGnRH-R-III can activate the protein kinase C and Ca^2+^ second messenger signalling pathways, which are the predominant mediators of LH and FSH biosynthesis and secretion ([@bib6], [@bib34]). However, receptor ligand selectivity measured *in vitro* does not necessarily correlate with *in vivo* functional significance nor does it determine the designation of cognate receptors. Maybe evolutionary recruitment of ligand--receptor pairing for particular physiological processes is not determined by selection according to the highest affinity for ligand binding or efficacy in inositol phosphate production.

Considering differences between the two chicken receptors, the possibility that cGnRH-R-III may differ from cGnRH-R-I in the rate of ligand-induced internalisation was anticipated because eight additional residues occur in the carboxyl-terminal tail of cGnRH-R-III, a domain that predisposes GnRH-Rs to rapid rates of internalisation ([@bib29]). A slightly greater rate of internalisation was measured for cGnRH-R-III compared with cGnRH-R-I. The region crucial for receptor internalisation of cGnRH-R-I is distal residue 336 in cGnRH-R-I ([@bib29]). In cGnRH-R-III, this region contains all eight of the additional residues that comprise the elongated tail. The spatial arrangement of amino acid residues in the carboxyl-terminus region of cGnRH-R-III may contribute to the increase in internalisation rate, given that the known residues important for internalisation are conserved between the two receptors ([@bib29], [@bib30]; [Fig. 1](#fig1){ref-type="fig"}A).

Both cGnRH-R-III and cGnRH-R-I have a significantly higher binding affinity for mammalian antagonist 27 compared with mammalian antagonists 135-18 and 135-25. GnRH-R-I showed a 56-fold higher binding affinity for antagonist 27 than the binding affinity at cGnRH-R-III. The observed low binding affinities of mammalian antagonists 135-25 and 135-18 are translated into similarly low potencies in their capacity to stimulate or inhibit inositol phosphate accumulation. The sizes of these effects are too small to accurately differentiate the two receptor subtypes.

Antagonist 27 showed inverse agonistic effects at both chicken receptors. Differences in binding affinity were translated into differences in antagonistic effects at the receptors, with antagonist 27 showing a 153-fold higher antagonistic effect at cGnRH-R-I than cGnRH-R-III. Therefore, it may be possible to utilise antagonist 27 to differentially block type I GnRH receptor function *in vivo* in order to study type III GnRH receptor physiology.

In summary, we directly compared pharmacological properties of cGnRH-R-I and cGnRH-R-III, and found both receptors to be similar in response to endogenous chicken GnRH ligands. Pharmacological profiling of the type I and type III GnRH receptors has established that GnRH-II is more selective and more potent in inositol phosphate accumulation at both receptors than cGnRH-I. cGnRH-R-III has a more rapid internalisation rate than cGnRH-R-I. Activation and inhibition by GnRH analogues acting on cGnRH-R-I and cGnRH-R-III has been characterised using a range ligands (sGnRH-III, mammalian antagonist 27, 135-18 and 135-25), furthering the pharmacological profile of both receptor subtypes.

The findings concerning ligand selectivity, G protein coupling and internalisation of cGnRH-R-III suggest that it could theoretically function similarly to cGnRH-R-I to regulate gonadotrophin synthesis. However, the predominant levels of cGnRH-R-III mRNA in the pituitary gland (1373-fold more than cGnRH-R-I), and the changes in expression patterns with age and sex suggest a distinct functional capacity of cGnRH-R-III compared with cGnRH-R-I.

However, further experiments are required to elucidate the role of cGnRH-R-III within the pituitary. Our studies suggest that evolutionary plasticity in the tissue-specific adoption of GnRH ligand and receptor subtypes for regulation of particular physiological functions may have occurred in birds. Birds appear to have adopted a strategy to regulate gonadotrophin synthesis and release, which utilises cGnRH-I and cGnRH-R-III pairing. The development of GnRH analogues such as antagonist 27 that differentially affect GnRH receptor subtype function will be valuable for determining the physiological roles of different ligands and receptor subtypes.
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![(A) Alignment of human, bullfrog, leopard gecko, African clawed frog and chicken GnRH receptor sequences. These are representative sequences of GnRH receptor types I, II and III. Motifs in ECL3 are depicted in bold and underlined. Ubiquitously conserved amino acid residues are shown with dark background shading. Boxed amino acids are as follows: 1 and 2, aspartic acid in the functional helix2/helix7 micro-domain of non-mammalian GnRH receptors; 3 and 4, conserved coupling arginine cage motif and alanine; 5, 6, 7 and 8, ligand binding residues, aspartic acid, asparagine, lysine and arginine respectively. Predicted transmembrane domains (TMD1--7) are indicated by a bold line. GnRH receptor subtypes are labelled according to the published terminology and presented in Roman numerals ([@bib47], [@bib15]). (B) A phylogenetic tree based on multiple sequence alignment of representative, reptilian, amphibian and avian GnRH receptor sequences. The tree was constructed using TreeTop phylogenetic tree prediction software ([@bib49]).](JOE080544f01){#fig1}

![Northern blot of pituitary (P), small intestine (SI) and testes (T) Poly (A)^+^ RNA samples from 14-week-old AIL male birds, hybridised with (A) cGnRH-R-III \[γ-^32^P\]-dATP 5′ end labelled oligoprobe and (B) actin alpha skeletal muscle (ACTA1) ^32^P-dCTP random primer labelled DNA probe. (C) Northern blot with pooled male and female cortex (C), pooled male and female muscle (M) and anterior pituitary glands (P^1^=female, P^2^=male) total RNA samples from white Leghorn layer type birds, hybridised with GnRH-R-III antisense riboprobe covering all four exons. The blot shows a single band in the pituitaries and no detectable bands in the muscle or cortex tissues. RNA size markers were run on the original gel and sizes were transferred to the image by interpolation. The position of the 28S and 18S rRNA is indicated and can be seen as areas of reduced background on the image. (D--F) Comparative quantitative real-time PCR analysis of cGnRH-R-I and cGnRH-R-III mRNA expression in tissues of pre-pubertal and sexually mature, male and female broiler chickens. (D) cGnRH-R-III mRNA expression per milligram of tissue. (E) cGnRH-R-I mRNA expression per milligram of tissue. (F) Ratio of absolute expression of cGnRH-R-III over cGnRH-R-I mRNA. Values are mean (mol/mg)±[s.e.m.]{.smallcaps}, \*\**P*≤0·01. P, pituitary; ME, median eminence; SI, small intestine; T, testes; O, ovary. (No significant differences were detected between male and female gonads). (G) Relationship between sex and age on pituitary cGnRH-R-III mRNA expression in pre-pubertal (*n*=6) and sexually mature (*n*=6), male (*n*=6; open columns) and female (*n*=6; solid columns) broiler chickens. Values are mean (mol/mg)±[s.e.m.]{.smallcaps}, \**P*≤0·05, \*\**P*≤0·01.](JOE080544f02){#fig2}

![(A) Ligand binding of cGnRH-R-I and cGnRH-R-III. Competitive displacement of ^125^I-\[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH with serial dilutions (10^−11^--10^−6^ M) of cGnRH-I (solid squares) and (10^−11^--10^−6^ M) GnRH-II (open squares) in COS-7 cells transiently transfected with cGnRH-R-I (dashed lines) and cGnRH-R-III (solid lines) expression constructs. The data presented are from four independent experiments each performed in triplicate. Non-specific binding, determined in un-transfected cells was subtracted from c.p.m. (B) Inositol phosphate production in response to (10^−11^--10^−6^ M) cGnRH-I (solid squares) and GnRH-II (open squares) in COS-7 cells transiently transfected with cGnRH-R-I (dashed lines) and cGnRH-R-III (solid lines) expression constructs. The data are from four independent experiments performed in triplicate. (C) cGnRH-R-I and cGnRH-R-III ligand induced internalisation rate. Per cent internalisation of ^125^I-\[His^5^-[d]{.smallcaps}-Tyr^6^\]-GnRH ligand mediated by cGnRH-R-I (solid triangle) and cGnRH-R-III (solid square). Data points are the mean±[s.e.m.]{.smallcaps} of four independent experiments each performed with six replicates. Non-specific binding, determined in un-transfected cells was accounted for.](JOE080544f03){#fig3}

![Inositol phosphate production in response to (10^−10^--10^−5^ M) mammalian antagonist 27 (A and C); 135-25 (E and G) and 135-18 (I and K) in COS-7 cells transiently transfected with cGnRH-R-I (filled squares (A, E and I)) and cGnRH-R-III (open squares (C, G and K)). The ability to inhibit inositol phosphate formation by mammalian antagonist 27 (B and D); 135-25 (F and H) and 135-18 (J and L) in the presence of 1 nM GnRH-II stimulation was measured in COS-7 transiently transfected with cGnRH-R-I (filled circles (B)) and cGnRH-R-III (open circles (D)). Inositol phosphate production in response to 10^−8^ M GnRH-II stimulation (asterisks). Non-stimulated basal inositol phosphate accumulation (diamonds). The data are the mean±[s.e.m.]{.smallcaps} of three independent experiments performed in triplicate.](JOE080544f04){#fig4}

###### 

Primary structure of GnRH analogues

  ------------------------------------ ------------------------------------------------------------ ------------------------------- ------------------------ ----- --------- ------------------------- ----- --------- ----- --------------------- -------
                                       **Position of amino acid**                                                                                                                                                                                  
                                       1                                                            2                               3                        4     5         6                         7     8         9     10                    
  **Peptide name**                                                                                                                                                                                                                                 
  GnRH-II                              pGlu                                                         His                             Trp                      Ser   His       Gly                       Trp   Tyr       Pro   Gly                   NH~2~
  cGnRH-I                              pGlu                                                         His                             Trp                      Ser   Tyr       Gly                       Leu   Gln       Pro   Gly                   NH~2~
  His^5^-[d]{.smallcaps}-Tyr^6^ GnRH   pGlu                                                         His                             Trp                      Ser   His       [d]{.smallcaps}-Tyr       Leu   Arg       Pro   Gly                   NH~2~
  sGnRH-III                            pGlu                                                         His                             Trp                      Ser   Tyr       Gly                       Trp   Leu       Pro   Gly                   NH~2~
  27                                   Ac-[d]{.smallcaps} Nal(2)[a](#tblfn1){ref-type="table-fn"}   [d]{.smallcaps}-α-Me-4-Cl-Phe   [d]{.smallcaps}-Trp      Ser   Ipr-Lys   [d]{.smallcaps}-Tyr       Leu   Arg       Pro   [d]{.smallcaps}-Ala   NH~2~
  135-18                               Ac-[d]{.smallcaps}-Nal(2)                                    [d]{.smallcaps}-4-Cl-Phe        [d]{.smallcaps}-Pal(3)   Ser   Ile       [d]{.smallcaps}-Ipr-Lys   Leu   Ipr-Lys   Pro   [d]{.smallcaps}-Ala   NH~2~
  135-25                               Ac-[d]{.smallcaps}-Nal(2)                                    [d]{.smallcaps}-4-Cl-Phe        [d]{.smallcaps}-Pal(3)   Ser   1-MePal   [d]{.smallcaps}-Ipr-Lys   Leu   Ipr-Lys   Pro   [d]{.smallcaps}-Ala   NH~2~
  ------------------------------------ ------------------------------------------------------------ ------------------------------- ------------------------ ----- --------- ------------------------- ----- --------- ----- --------------------- -------

Abbreviations for synthetic amino acids are: Nal(2), 3-(2-naphthyl) alanine; 4-Cl-Phe, 3-(4-chlorophenyl) alanine; α-Me-4-Cl-Phe, 2-methyl-3-(-chlorophenyl) alanine; Ipr-Lys, *N*^*ε*^-isopropyllysine.

###### 

Receptor binding and peptide-stimulated inositol phosphate accumulation in response to cGnRH analogues in COS-7 cells expressing cGnRH-R-I and cGnRH-R-III

  ------------ ---------------------------------------------- ---------------------------------------------- -------------------------------------------------- ---------------------------------------------- -------------------------------------------------- ------------------------------------------------
               **Ligand binding**                             **IP production**                                                                                                                                                                                   
               cGnRH-R-I                                      cGnRH-R-III                                    cGnRH-R-I                                          CGnRH-R-III                                                                                       
               *K*~i~ (nM)[a](#tblfn2){ref-type="table-fn"}   ED~50~ (nM)[b](#tblfn3){ref-type="table-fn"}   IC~50~ (nM)[c](#tblfn4){ref-type="table-fn"}       ED~50~ (nM)[b](#tblfn3){ref-type="table-fn"}   IC~50~ (nM)[c](#tblfn4){ref-type="table-fn"}       
  **Analog**                                                                                                                                                                                                                                                      
  cGnRH-I      10·8±1·59[d](#tblfn5){ref-type="table-fn"}     19·8±3·56[d](#tblfn5){ref-type="table-fn"}     2·8±0·20[d](#tblfn5){ref-type="table-fn"}                                                         4·38±0·18[d](#tblfn5){ref-type="table-fn"}         
  GnRH-II      0·51±0·07[d](#tblfn5){ref-type="table-fn"}     0·57±0·15[d](#tblfn5){ref-type="table-fn"}     0·7±0·14[d](#tblfn5){ref-type="table-fn"}                                                         0·8±0·14[d](#tblfn5){ref-type="table-fn"}          
  sGnRH-III    8·40±1·21[e](#tblfn6){ref-type="table-fn"}     9·31±4·31[e](#tblfn6){ref-type="table-fn"}     10·3±4·5[d](#tblfn5){ref-type="table-fn"}                                                         21±0·2[d](#tblfn5){ref-type="table-fn"}            
  27           0·38±0·09[e](#tblfn6){ref-type="table-fn"}     21·4±4·86[e](#tblfn6){ref-type="table-fn"}     Inverse agonist[e](#tblfn6){ref-type="table-fn"}   2·3±0·3[e](#tblfn6){ref-type="table-fn"}       Inverse agonist[e](#tblfn6){ref-type="table-fn"}   351±114[e](#tblfn6){ref-type="table-fn"}
  135-18       2090±156[e](#tblfn6){ref-type="table-fn"}      7260±105[e](#tblfn6){ref-type="table-fn"}      None[d](#tblfn5){ref-type="table-fn"}              2330±134[d](#tblfn5){ref-type="table-fn"}      1510±216[d](#tblfn5){ref-type="table-fn"}          3890±2027[d](#tblfn5){ref-type="table-fn"}
  135-25       14 200±1515[e](#tblfn6){ref-type="table-fn"}   8560±3402[e](#tblfn6){ref-type="table-fn"}     5970±2510[d](#tblfn5){ref-type="table-fn"}         245±207[d](#tblfn5){ref-type="table-fn"}       4860±807[d](#tblfn5){ref-type="table-fn"}          None[d,f](#tblfn5 tblfn7){ref-type="table-fn"}
  ------------ ---------------------------------------------- ---------------------------------------------- -------------------------------------------------- ---------------------------------------------- -------------------------------------------------- ------------------------------------------------

All experiments were performed on separate occasions in triplicate.

*K*~i~ values (binding affinities) for GnRH analogues.

ED~50~ values for agonist activity of GnRH analogues.

IC~50~ values for antagonism of IP production stimulated by 1 nM GnRH-II.

Data are mean±[s.e.m.]{.smallcaps} of three to four experiments.

Data are mean±[s.e.m.]{.smallcaps} of two to three experiments.

20·1±8·9=agonistic effect of peptide in presence of 1 nM GnRH-II.
